Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 31 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Lyka Labs Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 31, 2024, 8:20 am

Market Cap 564 Cr.
Current Price 158
High / Low 177/97.9
Stock P/E178
Book Value 27.7
Dividend Yield0.00 %
ROCE3.53 %
ROE5.07 %
Face Value 10.0
PEG Ratio2.13

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Lyka Labs Ltd

Competitors of Lyka Labs Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
MPS Pharmaa Ltd 8.05 Cr. 4.21 4.33/2.79 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 3,274 Cr. 300 390/17062.1 20.50.22 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 62.3 Cr. 83.9 94.9/27.023.8 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 35.4 Cr. 24.2 27.0/8.7446.0 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 84.3 Cr. 112 155/87.012.6 55.40.00 %14.4 %15.5 % 10.0
Industry Average19,528.12 Cr1,193.9155.65184.740.31%16.14%16.48%6.30

All Competitor Stocks of Lyka Labs Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales26.8124.2649.4473.8935.5735.1927.4925.5317.8222.2422.8827.9932.56
Expenses20.8018.0219.5428.2722.5522.5921.1820.5015.6118.9420.2423.8225.69
Operating Profit6.016.2429.9045.6213.0212.606.315.032.213.302.644.176.87
OPM %22.42%25.72%60.48%61.74%36.60%35.81%22.95%19.70%12.40%14.84%11.54%14.90%21.10%
Other Income0.70-0.500.47-3.200.58-2.270.950.98-5.950.020.38-0.180.54
Interest6.596.376.935.574.642.992.913.033.082.851.351.191.28
Depreciation2.122.022.133.522.249.463.593.623.473.473.473.592.84
Profit before tax-2.00-2.6521.3133.336.72-2.120.76-0.64-10.29-3.00-1.80-0.793.29
Tax %7.00%159.25%8.59%16.98%6.55%-607.08%6.58%46.88%-2.24%0.00%-7.22%22.78%38.60%
Net Profit-2.271.1419.5528.436.09-15.070.60-0.38-10.42-3.01-1.85-0.491.78
EPS in Rs-0.790.406.819.912.12-5.250.21-0.13-3.63-0.98-0.56-0.150.54

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1701271191661301106071618619493106
Expenses155991111391108763736567937689
Operating Profit15288282023-4-2-4201011717
OPM %9%22%7%17%16%21%-6%-3%-6%23%52%18%16%
Other Income1632548-241-300-4-41
Interest301927241519107202620127
Depreciation91291191011788171413
Profit before tax-80-3-34-8-20-15-62-1459-13-2
Tax %0%0%-45%-31%-5%19%5%59%-1%29%35%0%
Net Profit-8-1-5-54-7-19-6-63-1038-13-4
EPS in Rs-3.20-0.33-3.05-2.291.67-2.51-6.14-1.97-21.10-4.0313.59-4.30-1.15
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)87.50%-400.00%-275.00%-171.43%68.42%-950.00%84.13%480.00%-134.21%
Change in YoY Net Profit Growth (%)0.00%-487.50%125.00%103.57%239.85%-1018.42%1034.13%395.87%-614.21%

Lyka Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:%
5 Years:9%
3 Years:9%
TTM:45%
Compounded Profit Growth
10 Years:%
5 Years:7%
3 Years:19%
TTM:138%
Stock Price CAGR
10 Years:19%
5 Years:52%
3 Years:-11%
1 Year:28%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:-5%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:14 pm

MonthMar 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital22222222222828292929313336
Reserves44302022162115-43-54-15153563
Borrowings12716413712112611396141163130755935
Other Liabilities9611310077886776735242313034
Total Liabilities289329279242252229216200190186152157168
Fixed Assets931621221041331161081059894685858
CWIP47222730242831282618162328
Investments6000000000000
Other Assets143145130107948577686674677683
Total Assets289329279242252229216200190186152157168

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +11892712311127597992
Cash from Investing Activity +5-573717-13-3-4-0-0-67-9
Cash from Financing Activity +-13-26-60-30-19-10-233-12-63-222
Net Cash Flow364-1-0-3-19-310-5-6

Free Cash Flow

MonthJun 2014Jun 2015Mar 2012Mar 2013Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow-156.00-109.0015.00-99.00-101.00-103.00-117.00-98.00-145.00-143.00-29.00-58.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days21120912412197125754837357989
Inventory Days9991775690139656941566878
Days Payable236363220218266301216192141969198
Cash Conversion Cycle73-64-18-41-79-37-75-76-63-55568
Working Capital Days96-106-88-75-191-456-181-156-7163471
ROCE %10%2%10%7%9%-8%-5%-6%10%61%5%4%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters20.00%20.04%47.79%47.80%47.58%47.58%51.00%54.58%54.81%54.81%54.81%58.11%
FIIs2.07%1.13%1.12%0.76%0.57%0.37%0.18%0.17%0.18%0.17%0.17%0.15%
DIIs1.85%0.47%1.19%3.99%4.00%4.00%3.74%0.41%0.41%0.62%0.81%0.75%
Public76.08%78.36%49.89%47.45%47.85%48.05%45.08%44.84%44.61%44.41%44.21%40.99%
No. of Shareholders20,67227,72026,22026,96928,43328,51526,82027,20226,65226,42225,71725,716

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)-0.79-4.6313.57-4.07-21.29
Diluted EPS (Rs.)-0.79-4.6313.57-4.07-21.29
Cash EPS (Rs.)3.080.3219.45-0.61-19.03
Book Value[Excl.RevalReserv]/Share (Rs.)20.6314.884.70-8.75-5.27
Book Value[Incl.RevalReserv]/Share (Rs.)20.6314.884.70-8.75-5.27
Revenue From Operations / Share (Rs.)33.6030.3367.6530.0621.43
PBDIT / Share (Rs.)5.196.5935.997.41-0.20
PBIT / Share (Rs.)1.321.9929.944.50-2.99
PBT / Share (Rs.)-0.28-4.2920.65-4.93-21.57
Net Profit / Share (Rs.)-0.79-4.2913.40-3.52-21.83
NP After MI And SOA / Share (Rs.)-0.75-4.3013.59-4.03-21.10
PBDIT Margin (%)15.4421.7453.1924.63-0.94
PBIT Margin (%)3.926.5444.2514.98-13.96
PBT Margin (%)-0.83-14.1530.52-16.39-100.63
Net Profit Margin (%)-2.35-14.1319.80-11.69-101.84
NP After MI And SOA Margin (%)-2.23-14.1920.09-13.39-98.45
Return on Networth / Equity (%)-3.65-29.07292.380.000.00
Return on Capital Employeed (%)3.665.1299.579.17-6.41
Return On Assets (%)-1.58-8.7121.01-6.08-30.24
Long Term Debt / Equity (X)0.621.384.63-5.84-8.75
Total Debt / Equity (X)0.841.559.66-6.24-9.75
Asset Turnover Ratio (%)0.720.440.820.300.18
Current Ratio (X)1.351.360.520.590.54
Quick Ratio (X)1.091.140.440.500.43
Inventory Turnover Ratio (X)3.893.054.312.232.12
Interest Coverage Ratio (X)3.511.715.130.81-0.02
Interest Coverage Ratio (Post Tax) (X)0.540.513.230.65-0.46
Enterprise Value (Cr.)402.09381.55501.74229.87166.02
EV / Net Operating Revenue (X)3.624.102.592.672.70
EV / EBITDA (X)23.4218.854.8610.82-286.39
MarketCap / Net Operating Revenue (X)3.153.452.000.860.59
Price / BV (X)5.147.0729.17-2.89-2.55
Price / Net Operating Revenue (X)3.153.452.000.860.59
EarningsYield-0.01-0.040.10-0.15-1.65

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Lyka Labs Ltd as of December 31, 2024 is: 254.98

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 31, 2024, Lyka Labs Ltd is Undervalued by 61.38% compared to the current share price 158.00

Intrinsic Value of Lyka Labs Ltd as of December 31, 2024 is: 468.54

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 31, 2024, Lyka Labs Ltd is Undervalued by 196.54% compared to the current share price 158.00

Last 5 Year EPS CAGR: 83.75%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of -93.08, which is a positive sign.
  2. The stock has a low average Cash Conversion Cycle of -21.83, which is a positive sign.
  1. The stock has a low average ROCE of 8.25%, which may not be favorable.
  2. The company has higher borrowings (114.38) compared to reserves (13.00), which may suggest financial risk.
  3. The company has not shown consistent growth in sales (114.85) and profit (-6.54).

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lyka Labs Ltd:
    1. Net Profit Margin: -2.35%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 3.66% (Industry Average ROCE: 16.01%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -3.65% (Industry Average ROE: 15.93%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 0.54
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.09
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 178 (Industry average Stock P/E: 45.36)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.84
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 164.35 Cr. and Equity Capital is Rs. 28.69 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals4801/B & 4802/A, G.I.D.C. Industrial Estate, Ankleshwar Gujarat 393002companysecretary@lykalabs.com.
http://www.lykalabs.com
Management
NamePosition Held
Mr. Babulal JainChairman
Mr. Kunal GandhiManaging Director & CEO
Mr. Yogesh B ShahExecutive Director & CFO
Mr. Shashil MendosaNon Executive Director
Mr. Prashant GodhaNon Executive Director
Mrs. Dhara ShahIndependent Director
Mr. Neeraj GolasIndependent Director

FAQ

What is the latest intrinsic value of Lyka Labs Ltd?

The latest intrinsic value of Lyka Labs Ltd as on 31 December 2024 is ₹254.98, which is 61.38% higher than the current market price of ₹158.00. The stock has a market capitalization of 564 Cr. and recorded a high/low of 177/97.9 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹63 Cr and total liabilities of ₹168 Cr.

What is the Market Cap of Lyka Labs Ltd?

The Market Cap of Lyka Labs Ltd is 564 Cr..

What is the current Stock Price of Lyka Labs Ltd as on 31 December 2024?

The current stock price of Lyka Labs Ltd as on 31 December 2024 is 158.

What is the High / Low of Lyka Labs Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Lyka Labs Ltd stocks is 177/97.9.

What is the Stock P/E of Lyka Labs Ltd?

The Stock P/E of Lyka Labs Ltd is 178.

What is the Book Value of Lyka Labs Ltd?

The Book Value of Lyka Labs Ltd is 27.7.

What is the Dividend Yield of Lyka Labs Ltd?

The Dividend Yield of Lyka Labs Ltd is 0.00 %.

What is the ROCE of Lyka Labs Ltd?

The ROCE of Lyka Labs Ltd is 3.53 %.

What is the ROE of Lyka Labs Ltd?

The ROE of Lyka Labs Ltd is 5.07 %.

What is the Face Value of Lyka Labs Ltd?

The Face Value of Lyka Labs Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lyka Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE